Onyx Scientific receives commercial API license

Published: 4-Jun-2021
Regulatory

The license allows the company to support API projects from pre-clinical studies to low volume commercial manufacture

Onyx Scientific, a small molecule CDMO, has received a commercial API license for its UK facility.

The license, granted by the MHRA, allows the company to support API projects from pre-clinical studies to low volume commercial manufacture.

Denise Bowser, Commercial Director at Onyx, commented: “Over the years, we have worked towards building a strong reputation in helping drug developers with complex chemistry. This commercial API license is incredibly important as it marks the next phase in our growth and enables us to support customers from concept to commercialisation. We are now able to fill the gap in the market for small-scale commercial API requirements while maintaining our expertise in delivering early-stage programs.”

It’s envisaged the company’s 70-strong team will grow by around 50% in the next three years to support its clinical and commercial API manufacturing capabilities.

  • Companies:
  • Onyx Scientific
See more

You may also like

Manufacturing

Onyx Scientific eyes UK facility expansion for commercial API licence

Read more
Licence approval from the MHRA is expected this year and will see the British CRO take customers’ projects from concept to market

Trending Articles

  1. Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for successful market entry from the early stages of development, reports Frederick Duynslaeger, Senior CMC Writer at Ardena
  2. Overcoming CMC challenges in cell and gene therapy: part II Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC challenges inherent in producing cell and gene therapy (CGT) drugs
  3. Overcoming CMC challenges in cell and gene therapy: part I Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC challenges inherent in producing cell and gene therapy (CGT) drugs
  4. Innovating with purpose for safety and security of outcome Beyond the importance of increasing productivity and generating more output and value with the same input, new ideas and technologies from GEA take innovation a step further
  5. AskBio receives FDA Fast Track Designation for congestive heart failure gene therapy programme The fast-tracking allows the development and expedition of review processes for AB-1002, a gene therapy to promote production of a constituently active form of I-1c

Upcoming event

Cleanroom Conference UK

22–23 May 2024 | Exhibition | Birmingham, UK See all

You may also like

Manufacturing

Onyx Scientific eyes UK facility expansion for commercial API licence

Licence approval from the MHRA is expected this year and will see the British CRO take customers’ projects from concept to market
Design & Build

Facility expansion at CRO following record year

Onyx Scientific is set to increase the size of its UK-based site by more than 30% following the best performance in its 15-year history
Manufacturing

Onyx Scientific wins Cancer Research UK contract

To develop the chemistry and provide GMP synthesis of API for Phase I trial
Regulatory

Broughton receives flexible scope ISO 17025 accreditation

New certification allows accreditation without prior approval
Regulatory

Overcoming CMC challenges in cell and gene therapy: part II

Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC challenges inherent in producing cell and gene therapy (CGT) drugs
Regulatory

Overcoming CMC challenges in cell and gene therapy: part I

Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC challenges inherent in producing cell and gene therapy (CGT) drugs
Regulatory

AskBio receives FDA Fast Track Designation for congestive heart failure gene therapy programme

The fast-tracking allows the development and expedition of review processes for AB-1002, a gene therapy to promote production of a constituently active form of I-1c
Subscribe now